Gainers & Losers Of The Day: CATB, MCUR, BIOC, SSH, ZYNE.

Catabasis' phase II trial of Edasalonexent in boys affected by Duchenne muscular dystrophy is ongoing, and top-line results are anticipated in the first half of Q1 2017.

from RTT - Biotech http://ift.tt/2iHA9ir
via IFTTT